These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21829131)

  • 1. The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.
    Yamada A; Maeda K; Ishiguro N; Tsuda Y; Igarashi T; Ebner T; Roth W; Ikushiro S; Sugiyama Y
    Pharmacogenet Genomics; 2011 Sep; 21(9):523-30. PubMed ID: 21829131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose.
    Ieiri I; Nishimura C; Maeda K; Sasaki T; Kimura M; Chiyoda T; Hirota T; Irie S; Shimizu H; Noguchi T; Yoshida K; Sugiyama Y
    Pharmacogenet Genomics; 2011 Aug; 21(8):495-505. PubMed ID: 21691256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [¹¹C]telmisartan.
    Takashima T; Hashizume Y; Katayama Y; Murai M; Wada Y; Maeda K; Sugiyama Y; Watanabe Y
    Mol Pharm; 2011 Oct; 8(5):1789-98. PubMed ID: 21812443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan pharmacokinetics in Japanese renal transplant recipients.
    Miura M; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T
    Clin Chim Acta; 2009 Jan; 399(1-2):83-7. PubMed ID: 18838068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics-A Comprehensive Pharmacogenomic Study.
    Hirvensalo P; Tornio A; Launiainen T; Paile-Hyvärinen M; Tapaninen T; Neuvonen M; Backman JT; Niemi M
    Clin Pharmacol Ther; 2020 Oct; 108(4):885-895. PubMed ID: 32498119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects.
    Guo X; Chen XP; Cheng ZN; Luo X; Guo R; Chen L; Chen J; Chen B; Peng J; Li YJ
    Clin Chem Lab Med; 2009; 47(1):38-43. PubMed ID: 19072027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of genetic variants in UGT1A1, SLCO1B3, ABCB1, ABCC2, ABCG2, ORM1 on PK/PD of telmisartan in Chinese patients with mild to moderate essential hypertension
.
    Pei Q; Yang L; Tan HY; Liu SK; Liu Y; Huang L; Li RH; Wan Q; Huang J; Guo CX; Zuo XC; Li J; Yang GP
    Int J Clin Pharmacol Ther; 2017 Aug; 55(8):659-665. PubMed ID: 28518053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3.
    Shimizu K; Takashima T; Yamane T; Sasaki M; Kageyama H; Hashizume Y; Maeda K; Sugiyama Y; Watanabe Y; Senda M
    Nucl Med Biol; 2012 Aug; 39(6):847-53. PubMed ID: 22421430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uridine 5'-Diphospho-glucuronosyltransferase 1A3 (UGT1A3) Prediction of Hepatic Clearance of Organic Anion Transporting Polypeptide 1B3 (OATP1B3) Substrate Telmisartan by Glucuronidation Using In Vitro-In Vivo Extrapolation (IVIVE).
    Gabor-Worwa E; Kowal-Chwast A; Gaud N; Gogola D; Littlewood P; Smoluch M; Brzózka K; Kus K
    Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):393-403. PubMed ID: 38642299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers.
    Noh YH; Lim HS; Kim MJ; Kim YH; Choi HY; Sung HR; Jin SJ; Lim J; Bae KS
    Clin Ther; 2012 Jul; 34(7):1625-35. PubMed ID: 22721873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of telmisartan in healthy Chinese subjects after oral administration of two dosage levels.
    Zhang P; Zhang Y; Chen X; Li R; Yin J; Zhong D
    Arzneimittelforschung; 2006; 56(8):569-73. PubMed ID: 17009837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro glucuronidation of the angiotensin II receptor antagonist telmisartan in the cat: a comparison with other species.
    Ebner T; Schänzle G; Weber W; Sent U; Elliott J
    J Vet Pharmacol Ther; 2013 Apr; 36(2):154-60. PubMed ID: 22486410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene glucuronidation in human intestine, kidney, and liver microsomes and in human liver microsomes genotyped for the UGT1A1*28 polymorphism.
    Trdan Lusin T; Trontelj J; Mrhar A
    Drug Metab Dispos; 2011 Dec; 39(12):2347-54. PubMed ID: 21937736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan.
    Chen WQ; Shu Y; Li Q; Xu LY; Roederer MW; Fan L; Wu LX; He FZ; Luo JQ; Tan ZR; He YJ; Zhou HH; Chen X; Zhang W
    PLoS One; 2013; 8(8):e70341. PubMed ID: 23940561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers.
    Stangier J; Su CA; Schöndorfer G; Roth W
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1355-64. PubMed ID: 11185634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidating nonlinear pharmacokinetics of telmisartan: Integration of target-mediated drug disposition and OATP1B3-mediated hepatic uptake in a physiologically based model.
    Tsuchitani T; Tomaru A; Aoki Y; Ishiguro N; Tsuda Y; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2024 Jul; 13(7):1224-1237. PubMed ID: 38745377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of UGT1A1 Polymorphism, Gender and Triglyceride on the Pharmacokinetics of Telmisartan in Chinese Patients with Hypertension: A Population Pharmacokinetic Analysis.
    Huang L; Yang L; Huang J; Tan HY; Liu SK; Guo CX; Zuo XC; Yang GP; Pei Q
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):797-806. PubMed ID: 31254178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic UDP-glucuronosyltransferases responsible for glucuronidation of thyroxine in humans.
    Kato Y; Ikushiro S; Emi Y; Tamaki S; Suzuki H; Sakaki T; Yamada S; Degawa M
    Drug Metab Dispos; 2008 Jan; 36(1):51-5. PubMed ID: 17908920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPLC determination of telmisartan in human plasma and its application to a pharmacokinetic study.
    Shen J; Jiao Z; Li ZD; Shi XJ; Zhong MK
    Pharmazie; 2005 Jun; 60(6):418-20. PubMed ID: 15997829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats.
    Kim MS; Wang S; Shen Z; Kochansky CJ; Strauss JR; Franklin RB; Vincent SH
    Drug Metab Dispos; 2004 Sep; 32(9):909-14. PubMed ID: 15319330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.